<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1019">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880151</url>
  </required_header>
  <id_info>
    <org_study_id>C12-71</org_study_id>
    <secondary_id>2013-A00344-41</secondary_id>
    <nct_id>NCT01880151</nct_id>
  </id_info>
  <brief_title>Neuroelectrical Biomarkers for Alzheimer's Disease Stages</brief_title>
  <acronym>ESTIMATE</acronym>
  <official_title>NEw approacheS for The dIagnosis of AlzeiMer's diseAse Through neuroElectrical Changes in the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent diagnostic criteria for Alzheimer's disease (AD) recognize an extended spectrum of AD&#xD;
      stages as part of the disease, including a preclinical stage. This underscores the importance&#xD;
      of early prognosis of AD when it is still possible to influence the course of the disorder.&#xD;
      The investigators propose a comprehensive project which will target the data-driven modeling&#xD;
      of the disease development. This goal will be achieved by creating and validating a battery&#xD;
      of new sensitive biomarkers for clinical evaluation and prediction of AD in individuals. The&#xD;
      AD-related brain changes will be assessed by noninvasive functional EEG measured during an&#xD;
      episodic memory task in subjects at different stages of AD, as well as in healthy controls.&#xD;
      The novel functional biomarkers will be extracted using a rigorous multistage selection&#xD;
      procedure involving advanced methods for feature extraction, as well as statistics and&#xD;
      classification for optimal selection. The ESTIMATE project will serve as a first step in an&#xD;
      extensive array of research procedures which will enable the early clinical identification of&#xD;
      Alzheimer's disease in elderly individuals who could then take advantage of preventive&#xD;
      pharmaceutical therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2013</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency band charactersitics of the electrophysiological brain response</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Prodromal AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presence of memory impairment Absence of impairment in activities of daily life EEG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild AD dementia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presence of memory impairment Presence of impairment in activities of daily life EEG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EEG</intervention_name>
    <description>EEG recorded during a resting condition and during an episodic memory task condition</description>
    <arm_group_label>Healthy control group</arm_group_label>
    <arm_group_label>Mild AD dementia</arm_group_label>
    <arm_group_label>Prodromal AD</arm_group_label>
    <other_name>Electroencephalography</other_name>
    <other_name>Electrical Geodesics Incorporated</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 70-85 years old&#xD;
&#xD;
          -  Presence of memory impairment&#xD;
&#xD;
          -  Completed educational level: middle school&#xD;
&#xD;
          -  Visual and auditory acuity: normal or corrected-to-normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Monogenic AD&#xD;
&#xD;
          -  Presence of a neurological disorder&#xD;
&#xD;
          -  Stroke that has occurred in the last three months&#xD;
&#xD;
          -  Prohibited medications&#xD;
&#xD;
          -  Residence in skilled nursing facility&#xD;
&#xD;
          -  Illiteracy, is unable to count or to read&#xD;
&#xD;
          -  Claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Dubois, PhD,MD,Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Memory and Alzheimer's Disease, Pitie-Salpetriere Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Memory and Alzheimer's Disease, Pitie-Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2013</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Prodromal</keyword>
  <keyword>EEG</keyword>
  <keyword>ERP</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

